Management of HIV-Associated Cryptococcal Meningitis

Matthew R. Osborn, Andrej Spec, Patrick B. Mazi

Research output: Contribution to journalReview articlepeer-review


Purpose of Review: Cryptococcal meningitis remains a significant cause of mortality among people living with HIV. This review summarizes current practices and recent advances in the management of cryptococcal meningitis. Recent Findings: Results from recent clinical trials have improved understanding of optimal induction therapy for cryptococcal meningitis, with the most recent data supporting the use of a single high dose of liposomal amphotericin B followed by two weeks of flucytosine and fluconazole. Studies have also demonstrated significantly reduced mortality with therapeutic lumbar punctures in patients with cryptococcal meningitis. Despite advances in management, long-term mortality remains high and may continue even after completion of antifungal therapy, emphasizing the importance of immune restoration in people living with HIV. Summary: Cryptococcal disease remains prevalent among people living with HIV, especially in resource-limited settings. Advances in treatment strategies, as well as increased accessibility to antifungal drugs, screening tests, and antiretroviral therapy, are critical for reducing morbidity and mortality from cryptococcal meningitis.

Original languageEnglish
Pages (from-to)124-131
Number of pages8
JournalCurrent Fungal Infection Reports
Issue number2
StatePublished - Jun 2023


  • AIDS
  • Amphotericin B
  • Cryptococcal meningitis
  • Cryptococcus
  • Fluconazole
  • Flucytosine


Dive into the research topics of 'Management of HIV-Associated Cryptococcal Meningitis'. Together they form a unique fingerprint.

Cite this